Table 3.

Clinical features and tumor characteristics of patients according to the rs4646 polymorphism.

	CC (N = 145)	CT/TT (N = 162)	P
Age	53.7 ± 10.5	52.5 ± 11.0	0.33
BMI	28.5 ± 6.8	29.0 ± 6.8	0.52
Menopausal status	(N = 144)	(N = 159)	0.89
Premenopausal	47 (32.6%)	55 (35.6%)
Perimenopausal	9 (6.3%)	11 (6.9%)
Postmenopausal	88 (61.1%)	93 (58.5%)
History of postmenopausal hormone therapy	47/142 (33.1%)	49/162 (30.2%)	0.59
Racial/Ethnic distribution
Non-Hispanic whites (N = 154)	77/154 (50.0%)	77/154 (50.0%)	0.62
Hispanic whites (n = 112)	50/112 (44.6%)	62/112 (55.4%)
*Others (N = 41)	18/41 (43.9%)	23/41 (56.1%)
Receptor Status
ER	(N = 141)	(N = 153)	0.96
Positive	101/141 (71.6%)	110/153 (71.9%)
Negative	40/141 (28.4%)	43/153 (28.1%)
PR	(N = 137)	(N = 153)	0.37
Positive	85/137 (62.0%)	87/153 (56.9%)
Negative	52/137 (38.0%)	66/153 (43.1%)
HER2	(N = 130)	(N = 142)	0.62
Positive	27/130 (20.8%)	33/142 (23.2%)
Negative	103/130 (79.2%)	109/142 ((76.8%)
Triple negative	26/141 (18.4%)	30/156 (19.2%)	0.86
Progressive disease	17/137 (12.4%)	36/155 (23.2%)	0.02
Stage at diagnosis
Stage 0–II	118/144 (81.9%)	113/160 (70.6%)	0.02
III–IV	26/144 (18.1%)	47/160 (29.4%)
Estradiol (pg/ml)	24.1 ± 32.1	26.0 ± 24.4	0.71

Formats of cell entries are mean ± SD or frequency/n (%). BMI, body mass index;

^*African-Americans, Native Americans, Asians, and multiracial. ER, Estrogen receptor; PR, progesterone receptor; HER2, Human epidermal growth factor receptor 2. Bold values indicate that the p-value is statistically significant.